Drug Profile
VR 876 - PROFILE NEEDS TO BE DELETED - DO NOT RELEASE
Alternative Names: Breelib; VR-876Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Activaero GmbH
- Developer Bayer; Vectura
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Lung disorders; Pulmonary hypertension
Most Recent Events
- 22 Dec 2016 Phase III development is ongoing in World
- 02 Oct 2015 Phase III clinical trials in Lung disorders in World (Inhalation)
- 28 May 2014 Phase III clinical trials in Pulmonary hypertension in World (unspecified route)